Valuation: TaiRx, Inc.

Market Cap 1.28B 38.84M 34.61M 31.66M 28.83M 54.35M 3.67B 55.82M 380M 152M 1.94B 146M 143M 6.13B P/E 2024
-20.5x
P/E 2025 -11x
Enterprise Value 953M 28.85M 25.71M 23.51M 21.41M 40.36M 2.73B 41.45M 282M 113M 1.44B 108M 106M 4.56B EV / Sales 2024
286x
EV / Sales 2025 75.1x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+0.44%
1 week-8.76%
Current month-4.18%
1 month-26.37%
3 months-14.87%
6 months-33.04%
Current year-47.72%
1 week 11.1
Extreme 11.1
12.55
1 month 11.1
Extreme 11.1
15.4
Current year 11.1
Extreme 11.1
23.45
1 year 11.1
Extreme 11.1
23.6
3 years 11.1
Extreme 11.1
44
5 years 11.1
Extreme 11.1
89.5
10 years 11.1
Extreme 11.1
89.5
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 22/08/2011
Director of Finance/CFO - 05/10/2015
Director TitleAgeSince
Chairman - 22/08/2011
Director/Board Member - 18/12/2013
Director/Board Member - 22/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%-8.76%-51.38%-55.96% 38.86M
+3.80%+8.47%+64.65%+77.70% 66.87B
+1.63%+4.93%+24.89%+102.90% 56.55B
+0.07%+1.39%+12.75%+76.61% 57.2B
-0.30%-4.15%+25.47%+32.88% 43.47B
-7.66%-2.81%+211.63%+758.50% 42.8B
+2.40%+4.41%+20.71%+97.79% 42.95B
+1.59%-4.04%+97.66%+81.57% 32.11B
+7.50%+13.28%+28.05%+64.46% 34.01B
-2.51%-3.99%-42.67%+349.41% 24.13B
Average +0.71%+3.16%+39.18%+158.59% 40.01B
Weighted average by Cap. +0.91%+3.91%+51.41%+166.78%

Financials

2024 2025
Net sales 8.22M 249K 222K 203K 185K 348K 23.51M 357K 2.44M 974K 12.45M 934K 914K 39.29M 27.88M 843K 752K 687K 626K 1.18M 79.71M 1.21M 8.26M 3.3M 42.21M 3.17M 3.1M 133M
Net income -139M -4.2M -3.74M -3.42M -3.12M -5.88M -397M -6.04M -41.13M -16.45M -210M -15.77M -15.43M -663M -221M -6.69M -5.96M -5.45M -4.97M -9.36M -632M -9.61M -65.52M -26.2M -335M -25.11M -24.58M -1.06B
Net Debt -505M -15.28M -13.61M -12.45M -11.34M -21.37M -1.44B -21.95M -150M -59.81M -765M -57.34M -56.11M -2.41B -330M -10M -8.91M -8.15M -7.42M -13.99M -945M -14.36M -97.89M -39.14M -500M -37.52M -36.72M -1.58B
Projected Income Statement - Annual - TaiRx, Inc.
Logo TaiRx, Inc.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
Employees
-
Date Price Change Volume
05/11/26 NT$11.45 +0.44% 54,063
04/11/26 NT$11.40 -2.98% 85,503
03/11/26 NT$11.75 -4.08% 219,963
02/11/26 NT$12.25 +2.51% 105,356
30/10/26 NT$11.95 -4.78% 86,499
  1. Stock Market
  2. Stocks
  3. 6580 Stock